HER-2/neu transgene-modified dendritic cell (DC)-based vaccines are potent at eliciting HER-2/neu-specific antitumor immunity. In this study, we constructed a recombinant adenovirus RGD AdVneu with fiber gene modified by RGD insertion into the viral knob's H1 loop. We transfected DCs with RGD AdVneu, and assessed/compared HER-2/neu-specific humoral and cytotoxic T lymphocyte (CTL) responses and antitumor immunity derived from the original AdVneu-transfected DCs (DCneu1) and RGD AdVneu-transfected DCs (DCneu2). We demonstrated that DCneu2 displayed increased HER-2/neu expression by 8.3-fold compared to DCneu1. We also demonstrated that DCneu2 vaccination induced stronger HER-2/neu-specific humoral and CTL immune responses than DCneu1 vaccination. DCneu2 vaccination protected all the mice from HER-2/neu-expressing Tg1-1 tumor cell challenge in wild-type FVB/NJ mice, compared to a partial protection in DCneu1-immunized mice. In addition, DCneu2 vaccination also significantly delayed tumor growth than DCneu1 immunization (Po0.05) in Tg FVBneuN mice. Three immunizations of DCneu2 starting at the mouse age of 2 months also significantly delayed breast cancer development in Tg mice compared to DCneu2 vaccine (Po0.05). Importantly, DCneu2 vaccine reduced breast carcinogenesis by 9% in Tg mice with self HER-2/neu tolerance. Therefore, vaccination of fiber-modified adenovirus-transfected DCs to enhance expression of tumor antigens such as HER-2/neu is likely representative of a new direction in DC-based vaccine of breast cancer.
Introduction
The proto-oncogene HER-2/neu is a transmembrane protein consisting of a cysteine-rich extracellular domain that functions in ligand-binding and an intracellular domain with kinase activity. The HER-2/neu gene has been found to be amplified and/or overexpressed in numerous human malignancies such as ovarian and gastric carcinomas, and particularly in approximately 25-30% of breast cancers in humans, most commonly in invasive ductal carcinomas. 1 Its overexpression in breast cancer patients is associated with poor prognosis. 2 Studies of patients with HER2/neu-expressing tumors have demonstrated the existence of humoral and T-cell responses against the HER-2/neu antigen (Ag) 3 though insufficient to prevent tumor outgrowth. The existence of antibodies (Abs) and T cells reactive to HER-2/neu was first reported in patients with breast cancer whose tumors overexpressed HER-2/neu. 4 Since then, a number of other studies have also documented the presence of these endogenous immune responses, both humoral 3 and cellular, 5 against HER-2/neu. The existent immune responses to HER-2/neu, though they are of low magnitude, indicate that HER-2/neu is an immunologic target and a suitable candidate for HER-2/neu-targeted vaccine strategies.
Dendritic cells (DCs) are powerful Ag-presenting cells, 6 that play a central role in generating and directing immune responses through the processing of Ags and presentation of Ag epitopes in the context of surface major histocompatibility complex (MHC) molecules to interact with T cells. DCs also express a full complement of co-stimulatory molecules and cytokines that are required to sustain and direct the immune responses 7, 8 Thus, DCs have been extensively used for cancer vaccines. Major efforts at developing antitumor vaccines have focused on harnessing DCs to effectively present tumor Ags to the immune system. DC-based vaccines by using DCs pulsed with synthetic peptides based on tumor Ags 9-11 mutant oncogenes 12 or immunoglobulin idiotypes, 13 expressed by tumors have been applied in clinical trials. The complexes of MHC class I and tumor peptides on DCs are recognized by the T-cell receptor of CD8 þ T cells, leading to activation and differentiation to cytotoxic T lymphocytes (CTLs). DCs pulsed with MHC class I-restricted HER-2/neu tumor peptide were able to induce CTL-dependent antitumor immune responses in vitro and in vivo 14, 15 However, peptide loading has a number of potential drawbacks including a need for detailed knowledge of the Ag sequence, identification of the recipient MHC molecule, and a requirement for a favorable binding affinity of the peptide for the MHC molecule. Peptide binding half-lives may be brief 16, 17 and the ability of a peptide to stimulate an Ag-specific CD8
þ CTL response correlates with the stability of this complex. 18 An alternative strategy is to load DCs with tumor protein lysates. 19, 20 Tumor lysates, however, contain many Ags, most of which are not tumor specific. As CD4 þ helper T (Th) cells triggered by the complexes of MHC class II and tumor peptide on DCs play an important role in facilitating antitumor immunity by augmentation of the CTL responses, 21 DCs have been engineered with recombinant adenoviral vectors (AdVs) to express HER-2/neu Ag containing both MHC class I-and II-restricted tumor peptides. 22, 23 It has been demonstrated that these engineered DCs can elicit both HER-2/neu-specific CTL and Th clones. 24 and stimulate antitumor immunity against challenge of HER-2/neu-positive tumor cells in vivo 22, 23 leading to phaseI/II clinical trials. 25, 26 However, there are limited studies evaluating the use of HER-2/neutargeted DC-based vaccination in rat HER-2/neu-gene transgenic (Tg) mice with self HER-2/neu tolerance. 27 We have previously demonstrated that vaccination of DCs transfected with AdVHER-2/neu stimulates HER-2/neuspecific CD8
þ CTL responses and immunity against challenge of HER-2-expressing colon cancer cells MCA26/HER-2 in wild-type animal model. 23 Recently, we have also demonstrated that vaccination of DCs transfected with AdVHER-2/neu stimulates more efficient HER-2/neu-specific CD8 þ CTL responses and antitumor immunity than DNA vaccine using pcDNAneu vector in wild-type FVB/NJ mice, 28 However, vaccination of DCs transfected with AdVHER-2/neu cannot reduce tumorigenicity of spontaneous development of breast cancer in Tg FVBneuN mice, though it delays the breast cancer development.
In this study, we constructed a recombinant fibermodified RGD AdVneu vector with RGD insertion into fiber knob HI loop and engineered bone marrow (BM)-derived DCs with RGD AdVneu to enhance the transgene HER-2/neu expression. We then compared the efficiency of HER-2/neu-specific CD8 q ) mice were obtained from Jackson Laboratories (Bar Harbor, ME). All mice were approximately 4-6 weeks old and housed in the Saskatoon Cancer Centre animal facility. All animal experiments were approved by the University Committee on Animal Care Committee in accordance with the Canadian Council for Animal Care guidelines.
Construction of fiber-modified RGD AdVneu-expressing HER-2/neu The recombinant AdVs including the control AdV pLpA without any transgene insertion and the original AdVneuexpressing transgene neu were previously generated in Dr Xiang's laboratory. 28, 30 The fiber-modified RGD AdVGFP expressing the marker gene green fluorescent protein (GFP) was obtained from Dr Zheng (NIH, Bethesda, MD). Addition of an RGD motif to the HI loop of the AdV fiber, forming RGD AdVneu in our system, has been shown to improve transduction of a variety of cell types. [31] [32] [33] The recombinant fiber-modified adenovirus Engineered DC vaccine in breast carcinoma S Sas et al RGD AdVneu-expressing the transgene HER-2/neu was constructed using the AdEasy system (Stratagene, La Jolla, CA) as previously described. 34 The fiber gene was modified by insertion of RGD motif into the viral HI loop similarly to the method described by Liu et al. 35 Briefly, the pAdEasy-1 vector was digested with BamHI, resulting in 21.7 and 11.7-kb DNA fragments. The 11.7-kb fragment was gel purified and inserted into pCRBlunt (Invitrogen, Carlsbad, CA) to form a pCR11.7 vector. The pCR11.7 vector was digested with EcoRI, resulting in 9.3-and 5.6-kb DNA fragments. The 9.3-kb fragment containing the pCRBlunt backbone underwent selfligation, forming pCR9.3 vector. PCR amplification was used to replace the DNA sequence within the StuI-AflII sites of the fiber knob domain in pCR9.3 vector. In PCR, the sense primer 1 (5 0 -caacaaaggcctttacttgtttacagctt ca-3 0 ) and the anti-sense primer 2 (5 0 -tgacatagagtactggtt tagttttgtctccgtttaag-3 0 ) were used to amplify a 680-bp P1 þ P2 fragment (nucleotides 31950-32630 of the AdV5 genome), whereas the sense primer 3 (5 0 -actaaaccagtactc tatgtcattttcatgggactggt-3 0 ) and the anti-sense primer 4 (5 0 -tggacagcgacatgaactttaagtgagctg-3 0 ) were used to amplify a 435-bp P3 þ P4 fragment (nucleotides 32690-33125 of the AdV5 genome). The P1 þ P2 and P3 þ P4 fragments were gel purified, mixed and joined by PCR using P1 and P4, resulting in a 1.1-kb fragment. This fragment contains part of the knob sequence of AdV5 with AflII (nucleotide 31950) and StuI (nucleotide 33125) sites. A deletion was created from 32631 to 32689 by removing amino-acid residues VTLTI TLNGT QETGD TTPSA, and incorporating a single mutation from T to A (underlined) to create a ScaI site (boldface) in the HI loop. Plasmid pCR9.3(AS) was constructed by inserting the 1.1-kb PCR fragment into the pCR9.3 vector. A duplex was formed by annealing two complimentary oligonucleotides (5 0 -aacactaaccattacactaaacggtacacaggaaacaggagacacaactt gcgactgtagaggagactgcttttgtccaagtgcat-3 0 and 5 0 -atgcacttgg acaaaagcagtctcctctacagtcgcaagttgtgtctcctgtttcctgtgtaccgtt tagtgtaatggttagtgtt-3 0 ). This 86-bp duplex was cloned into ScaI-digested pCR9.3(AS), forming the pCR9.3(RGD) plasmid, which contains the AdV5 complete sequence (nucleotide 31950-33125) and an additional RGD-4C sequence (CDCRGDCFC) in the HI loop (between nucleotides 32679 and 32680). The previously generated 5.6-kb fragment was inserted into EcoRI-digested pCR9.3(RGD) to form pCR11.7(RGD). The resulting 11.7-kb BamHI band from pCR11.7(RGD) was ligated into the previous 21.7-kb BamHI fragment of pAdEasy-1, resulting in pAdEasy(RGD). This 33.4-kb plasmid contains the pAdEasy-1 sequence plus an additional RGD-4C sequence in the HI loop. All of the insert orientations within the vectors were determined by dideoxy nucleotide sequencing method and restriction enzyme-digestion analysis. The shuttle vectors pShuttleneu with the rat neu gene and the control pLpA without any transgene were used. 28, 30 The PmeI-digested shuttle vectors were then co-transformed into BJ5183 E. coli cells already containing the backbone vector pAdEasy(RGD) for increased efficiency of homologous recombination 36 to form the recombinant vectors RGD AdVneu (Figure 1 ). The recombinant RGD AdVneu vector was linearized by PacI digestion, and then transfected into 293 cells using Lipofectamine (Gibco/BRL, Burlington, Ontario, Canada) to generate the fiber-modified adenovirus RGD AdVneu with the neu transgene. All recombinant adenoviruses were amplified in 293 cells, purified by a series of cesium chloride ultracentrifugation gradients and stored at À80 1C until use.
Preparation of BM-derived DCs
BM-derived DCs were prepared as described previously. 28 Briefly, BM cells from femora and tibia from FVB/NJ mice were depleted of red blood cells with 0.84% Trisammonium chloride and plated in DC culture medium (DMEM plus 10% FCS, GM-CSF (20 ng ml
À1
) and IL-4 (20 ng ml À1 )). Nonadherent granulocytes, T and B cells were gently removed and fresh media were added on the third day. After 2 days, loosely adherent proliferating DC aggregates were dislodged and replated. Nonadherent cells were harvested on the sixth day and DCs generated in this manner displayed typical morphologic features of DCs (that is, numerous dendritic processes). 
Adenovirus transduction of DCs
To assess the optimal multiplicity of infection (MOI) for maximal transgene expression, DCs were transfected with AdVGFP and RGD AdVGFP at various MOIs for 1 day and examined by flow cytometry. The number of transfected DCs expressing GFP at various MOIs was calculated. The above DCs were further incubated with the fiber-modified RGD AdVneu, the original AdVneu without fiber modification and the control RGD AdV pLpA without transgene insertion at MOI of 150, respectively. Following the viral adsorption for 1 h at 371, the DC culture medium was replaced with DMEM plus 10% FCS, and the DCs were incubated for another 24 h at 371. DCs transfected with RGD AdV pLpA , AdVneu or RGD AdVneu were termed DC pLpA , DCneu1 and DCneu2, respectively.
Flow cytometric analysis
For phenotypic analysis, DCs, DCneu1 and DCneu2 cells were stained with anti-HER-2/neu Ab, followed with FITC-conjugated goat anti-mouse IgG Ab or a panel of biotin-conjugated Abs followed with FITC-streptavidin, respectively, and then analyzed by flow cytometry. For analysis of HER-2/neu downregulation, 0.5 Â 10 6 Tg1-1 tumor cells were incubated with serum from immunized mice (1:50) for 24 h, and then analyzed for HER-2/neu expression using biotin-conjugated anti-neu Ab followed with FITC-avidin by flow cytometry.
RT-PCR
Total RNA was extracted from DCs, DCneu1 and DCneu2 using RNeasy Mini Kit (Qiagen, Mississauga, Ontario, Canada). Isolated RNA was used as a template for cDNA synthesis using the SuperScript First-strand Synthesis System for reverse transcription (RT)-PCR (Invitrogen), according to the instructions provided by the manufacturer. Briefly, 5 mg of RNA was incubated in 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 5 mM MgCl 2 , 10 mM dithiothreitol, 0.5 mM of each dNTP, 0.5 mg Oligo(dT) 12À18 , 40 units of RNase inhibitor and 50 units SuperScript II reverse transcriptase enzyme, for a final volume of 20 ml. The reaction was terminated by incubating the sample at 42 1C for 50 min followed by 70 1C for 15 min. The sample was then treated with 1 unit of RNase A to remove the remaining RNA. Samples were used either immediately for PCR or stored at À20 1C until needed. A predetermined amount of template DNA/ cDNA were used in PCR reactions in a volume of 100 ml containing 20 mM Tris-HCl (pH 8.0), 20 mM KCl, 1.5 mM MgCl 2 , 1 mM dNTP mix (dATP, dCTP, dGTP, dTTP), 10 ng of primers including the forward primer (5 0 -agattgccaaggggatgagc-3 0 ) and the reverse primer (5 0 -ctggatgaccacaaaacgctg-3 0 ) for neu gene, the forward primer (5 0 -tgttctctgggaaatcgtgg-3 0 ) and the reverse primer (5 0 -ttggatggtcttggtccttagc-3 0 ) for IL-6 gene and the forward primer (5 0 -caatcacgctacctcctctttttg-3 0 ) and the reverse primer (5 0 -cactctgtaagggtctgcttctcc-3 0 ) for IL-12 gene, and 2.5 units of Taq polymerase (Invitrogen). The PCR cycle includes the initial DNA denaturing step at 94 1C for 5 min followed by 25-30 amplification cycles at 94 1C for 1 min, 56-58 1C for 1 min and 72 1C for 1 min followed with a final termination step for 10 min at 72 1C. One-tenth of the reaction volume was resolved by standard agarose gel electrophoresis after PCR amplification. Water was used as the template to serve as the negative controls. A positive control reaction was used for RT-PCR samples using the forward primer (5 0 -caggttgtctcctgcgactt-3 0 ) and the reverse primer (5 0 -cttgctcagtgtccttgctg-3 0 ) to detect the expression of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase.
Indirect cell-based ELISA To identify the presence and subtypes of tumor-specific Abs, an indirect cell-based enzyme-linked immunosorbent assay (ELISA) was performed as described previously. 28, 37 Briefly, 1 Â 10 5 Tg1-1 cells were plated into 96-well plates and incubated overnight to allow for cell attachment to the plate then fixed by adding 0.2% (v/ v) gluteraldehyde solution (Sigma-Aldrich Canada Ltd, Oakville, Ontario, Canada) to the wells and incubating the plate at 4 1C for 15 min. The wells were then washed three times with phosphate-buffered saline (PBS) with 0.05% Tween 20 (Bio-Rad, Missisauga, Ontario, Canada), then blocked with 3% bovine serum albumin 38 (w/v) in PBS. Serum samples from mice immunized with DC pLpA (control), DCneu1 and DCneu2, respectively were diluted at a ratio of 1:50 in PBS and added to the wells and the plate was incubated for 1 h at 37 1C. Following this, the plate was washed with PBS with 0.05% (v/v) Tween 20 and incubated with either biotin-conjugated anti-mouse IgG 1 or IgG 2a Ab for 1 h followed by additional washes and the addition of streptavidin-conjugated peroxidase to the plate. Next, 3,3 0 ,5,5 0 -tetramethylbenzidine (TMB) substrate (TMB substrate reagent set; Pharmingen) was added to each well and incubated for 30 min followed by the addition of 2 N H 2 SO 4 to stop the reaction. Developed plates were read on a Bio-Rad Model 3550 microplate reader (Bio-Rad) at a wavelength of 450 nm.
Tetramer staining FVB/NJ mice were immunized with irradiated (3000 rad) DC pLpA (control), DCneu1 and DCneu2 (1 Â 10 6 cells per mouse) twice 2 weeks apart, respectively. Eight days after the boost, spleens were removed from immunized mice for preparation of single cell suspensions by pressing the spleens against fine nylon mesh and red blood cells were lysed with 0.84% Tris-ammonium chloride solution. The red blood cell-depleted splenic lymphocytes (5 Â 10 6 ) were co-cultured in 24-well plates with 2 Â 10 5 irradiated (20 000 rad) Tg1-1 cells per well containing 2 ml of DMEM plus 10% FCS with IL-2 (20 U ml À1 ). After 5 days, the activated T cells were stained for phycoerythrin (PE)-labeled H-2D q /PDSLRDLSVF tetramer (NIH Tetramer Facility, Atlanta, GA) and FITC-conjugated anti-CD8 Ab, and analyzed by flow cytometry. 39 In vitro tumor cell proliferation assay In tumor cell proliferation assay, Tg1-1 or CaD1 tumor cells (2 Â 10 4 cells per well) mixed with sera (1:50) from Engineered DC vaccine in breast carcinoma S Sas et al immunized mice were plated in a 96-well tissue culture plate and incubated at 37 1C. 28 Normal mouse sera and anti-HER-2/neu Ab (5 mg ml À1 ) were used as negative and positive controls, respectively. After 5 days, cell proliferation was measured by MTT assay using CellTiter 96 Non-radioactive Cell Proliferation Assay kit (Promega, Madison, WI). Plates were read at 595 nm using a BioRad Model 3550 microplate reader. Inhibition was calculated by (blank absorbance-experimental absorbance)/(blank absorbance-background absorbance) Â 100, where blank values refer to wells with no serum added and background values refer to wells with no cells added.
In vivo cytotoxicity assay
In vivo cytotoxicity assay was also performed as previously described. 28, 40 Briefly, FVB/NJ mice were immunized with DC pLpA (control), DCneu1 and DCneu2 (1 Â 10 6 cells per mouse) twice 2 weeks apart, respectively. Splenocytes derived from FVB/NJ mice were incubated with varying concentrations of carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes) ranging from high (3.0 mM, CFSE high ) to low (0.6 mM, CFSE low ) concentrations. CFSE high cells were pulsed with the HER-2/neu peptide (PDSLRDLSVF) and washed extensively, whereas the CFSE low cells were pulsed with the irrelevant LCMN peptide (RPQASGVYM). Six days after the last immunization, HER-2/neu-pulsed CFSE high and LCMNpulsed CFSE low cells were used as HER-2/neu-specific and nonspecific target cells, respectively, and co-injected intravenously (i.v.) at a ratio of 1:1 into the immunized mice. Sixteen hours after injection, spleens were removed to analyze residual HER-2/neu-specific CSFE high and nonspecific CFSE low target cells remaining in recipients' spleens by flow cytometry, respectively.
28
Vaccination of mice For evaluation of tumor immunity, the wild-type FVB/NJ and the Tg FVBneuN mice were vaccinated s.c. with DC pLpA (control), DCneu1 and DCneu2 (1 Â 10 6 cells per mouse) twice with a 14 day interval, respectively. Ten days after the boost, mice (n ¼ 8 per group) were challenged by s.c. injection of 3 Â 10 5 (low dose) or 1 Â 10 6 (high dose) Tg1-1 cells. Animal mortality and tumor growth were monitored daily for up to 40 days. For evaluation of tumor prevention, the Tg FVBneuN mice at the age of 2 months were vaccinated s.c. with DCneu1 and DCneu2 (1 Â 10 6 cells per mouse) at 1 month intervals, for a total of three vaccinations. Spontaneous breast tumor development was monitored weekly for up to 12 months. In the above animal studies, mice having an average tumor diameter greater than 10 mm were euthanized for humanitarian reasons.
Statistical analyses
Statistical analyses were performed using Prism software (GraphPad Software Inc., San Diego, CA) to form Kaplan-Meier survival chart and to perform logrank test to compare mouse survival and tumor development between groups. 41 To determine the significance of differences between groups, Student's t-tests were performed. P-values less than 0.05 (Po0.05) were considered statistically significant.
Results

RGD AdVGFP-transfected
þ T cells with AdVGFP transfection was obtained at MOIs of X200, whereas a maximal transfection of 85% GFP-positive CD8 þ T cells with RGD AdVGFP transfection was obtained at MOIs of X150, indicating that the transfection efficiency of RGD AdVGFP is higher than that of AdVGFP. Therefore, MOI of 150 was selected for transfection of DCs with RGD AdVGFP in this study. The expression of various cell surface molecules by AdV transfection was analyzed as previously described. 28 Both RGD AdVneu-and AdVneumediated transfections led to a mild-to-moderate upregulation of CD40, CD54, CD80 and CD86 expression on DCneu2 and DCneu1 cells (Figure 2a) , relative to the untreated DCs, indicating that these DCs became a more mature form of DCs. In addition, DCneu1 and DCneu2 cells also upregulated secretion of IL-6 and IL-12 ( Figure 2b) . Transfection of the control AdVpLpA also led to a mild-to-moderate upregulation of CD40, CD54 and CD80 expression on DC pLpA cells, and IL-6 and IL-12 secretion by DC pLpA cells (data not shown) as did DCneu1 and DCneu2, indicating that these upregulations are mostly derived from the AdV-mediated transduction. More importantly, the expression of HER-2/neu was greatly upregulated in DCneu2 cells by 8.3-fold ( Figures  2b and c) , compared to that of DCneu1, indicating that the transduction by RGD AdVneu is more efficient than that by AdVneu.
DCneu2 vaccine induces stronger HER-2/neu-specific humoral immune responses than DCneu1
Tumor rejection and growth has been shown to be associated with interferon-g and IgG 2a -dominant Th1 and IL-4 and IgG 1 dominant Th2 type immune response, respectively. 42 To examine the type of immune response derived from these HER-2/neu-targeted DC vaccines, FVB/NJ mice were immunized twice with DCneu1 or DCneu2, and the sera collected 2 weeks after the last immunization. The presence of HER-2/neu-specific IgG 1 and IgG 2a Abs, indicative of a Th2-and Th1-type immune response, respectively, were assessed by an indirect cell-based ELISA using Tg1-1 tumor cells grown in 96-well plates. Serum samples (1:80) were incubated on the plates, followed by peroxidase-conjugated goat anti-mouse IgG 1 or IgG 2a Ab. As shown in Figure 3a 
DCneu2-derived HER-2/neu-specific Ab induces downregulation of HER-2/neu expression and inhibits in vitro growth of Tg1-1 tumor cells
Previous studies have shown that the Abs recognizing HER-2/neu induced HER-2/neu downregulation and growth inhibition of tumor cells. 43 To assess the potential effect, Tg1-1 tumor cells expressing HER-2/neu were incubated with the sera of mice immunized with DCneu1 and DCneu2. As shown in Figure 3b , the sera derived from DCneu2-immunized mice resulted in more apparent downregulation of HER-2/neu expression on Tg1-1 cells compared to DCneu1-immunized mice. As HER-2/neu expression is related to tumor cell growth, we then examined whether the presence of anti-HER-2/neu Ab affected Tg1-1 cell proliferation in vitro. As shown in Figure 3c , the sera from DCneu2-immunized mice clearly inhibited B76% of Tg1-1 cell growth in vitro after 5 days, compared to B48% growth inhibition of Tg1-1 cells incubated with sera from DCneu1-vaccinated mice (Po0.05). Meanwhile, sera from the immunized mice did not inhibit growth of HER-2/neu-negative CaD1 tumor cells, indicating that the growth inhibition is HER-2/ neu-specific (data not shown).
DCneu2 vaccine induces stronger HER-2/neu-specific CD8
þ T-cell proliferation than DCneu1 To assess HER-2/neu-specific CD8 þ T-cell responses, the wild-type FVB/NJ mice were immunized twice with DCneu1 or DCneu2, and 8 days later their splenic lymphocytes were co-cultivated with irradiated Her-2/ neu-expressing Tg1-1 tumor cells. After 5 days, the activated T cells were harvested, stained with PE-labeled H-2D q /PDSLRDLSVF tetramer (PE-tetramer) and FITC-anti-CD8 Ab (FITC-CD8), and analyzed by flow cytometry. As shown in Figure 4a Engineered DC vaccine in breast carcinoma S Sas et al T-cell population was significantly higher in DCneu2-immunized mice than that (B18%) in DCneu1-immunized mice (Po0.05), indicating that DCneu2 immunization stimulates stronger HER-2/neu-specific CD8 þ T-cell proliferation than DCneu1 immunization.
DCneu2 vaccine stimulates more efficient HER-2/neu-specific CTL effector function than DCneu1
To analyze the specific antitumor effector function induced by vaccination of mice with DCneu1 and DCneu2, an in vivo cytotoxicity assay was performed. This assay involved differentially CFSE-labeled peptide-pulsed splenocytes, using CFSE high (HER-2/neu peptide-pulsed)-and CFSE low (LCMN peptide-pulsed)-labeled cells, transferred i.v. into recipient DCneu1-and Engineered DC vaccine in breast carcinoma S Sas et al DCneu2-immunized mice, respectively. Flow cytometry analysis was performed to examine the ability of activated T cells in induction of specific killing of HER-2/neupulsed CFSE high -labeled splenocytes (HER-2/neu-specific target cells). In Figure 4b , the residual HER-2/neuspecific CFSE high -labeled target cells remained unchanged in the spleens of the control mice. However, there was a 36% decrease in DCneu1-immunized mice and a greater degree of loss (51%) in DCneu2-immunized mice, indicating that DCneu2 immunization stimulates more efficient HER-2/neu-specific CTL effector function than DCneu1 immunization.
DCneu2 vaccine induces more efficient protective HER-2/neu-specific immunity than DCneu1 in wild-type FVB/NJ mice To determine whether the antitumor immunity derived from this HER-2/neu-targeted vaccine could induce protection against tumor growth, FVB/NJ wild-type mice were left untreated or vaccinated twice with DCneu1 or DCneu2. The mice were then challenged 10 days later with 0.3 Â 10 6 Tg1-1 tumor cells. As shown in Figure 5a , the wild-type mice immunized with DCneu1 and DCneu2 all showed 100% protection against Tg1-1 tumor cell challenge, compared to that of control mice which all died within 35 days after tumor cell challenge (Po0.05). To determine the difference in protective immunity between DCneu1-and DCneu2-immunized mice, a second protection study was performed in the wild-type FVB/N mice by challenging the mice with a higher dose of Tg1-1 tumor cells (1 Â 10 6 cells per mouse). The survival curve shown in Figure 5b revealed that DCneu1 immunization was only able to protect only 25% of the mice, whereas DCneu2 immunization was able to significantly protect 100% of the mice from tumor growth (Po0.05), indicating that DCneu2 immunization induces more efficient antitumor immunity in wild-type FVB/N mice than DCneu1 immunization. In the above animal studies, both DCneu1 and DCneu2 vaccinations could not protect any mice from challenge of CaD1 tumor cells without expression of HER-2/neu (data not shown), indicating that the immunity induced by DCneu1 and DCneu2 is HER-2/neu specific.
DCneu2 vaccine induces more efficient protective HER-2/neu-specific immunity than DCneu1 in Tg FVBneuN mice To assess whether the above results can be translated into the Tg FVBneuN mouse model, the same protection study was performed in the Tg mice. FVBneuN mice were vaccinated with DC pLpA (control), DCneu1 or DCneu2 twice, and then challenged 10 days later with Tg1-1 tumor cells. As shown in Figure 6a , tumor growth was significantly delayed in DCneu1-and DCneu2-immunized group compared to the control group (Po0.05), indicating both DCneu1 and DCneu2 immunizations induce HER-2/neu-specific immune responses. Although no mice survived in both DCneu1-and DCneu2-immunized mouse groups, the Tg mice immunized with DCneu2 had a significant delay in tumor growth, compared to that of DCneu1-immunized mice (Po0.05), indicating that DCneu2 immunization also induces more efficient antitumor immune responses in Tg FVBneuN mice than DCneu1 immunization.
DCneu2 vaccine reduces breast carcinogenesis in Tg FVBneuN mice
To determine whether the DCneu2-induced antitumor immunity could reduce breast carcinogenesis in Tg mice, the Tg FVBneuN mice at the age of 2 months were vaccinated s.c. with DC pLpA (control), DCneu1 and DCneu2 at 1 month intervals, for a total of three vaccinations. As shown in Figure 6b , both DCneu1 and DCneu2 immunizations induced a significant delay in tumor formation than the control group (Po0.05). In addition, DCneu2 immunization induced a more significant delay in tumor formation than DCn5u1 vaccination (Po0.05), confirming that DCneu2 immunization induces more efficient antitumor immune responses in Tg FVBneuN mice than DCneu1 immunization. Interest- 
Discussion
Retrovirus and adenovirus (AdV) are commonly used for delivery of transgenes to cells or tissues. 44 Retroviruses integrate their genome into the host DNA of dividing cells, and this provides the possibility of long-term transgene expression. However, its random integration may cause insertional mutagenesis in the host cells. Recently, it has been shown that retroviral vectors can cause leukemia formation. 45 However, the use of AdVs is relatively safe due to its low potential for insertional mutagenesis. 46 An efficient infection of target cells by AdVs requires two predominant viral-host cell receptor interactions. Primary adsorption of AdVs relies on the interaction of the viral knob domain with a cellular surface receptor designated coxsackievirus and adenovirus receptor (CAR). 47 Subsequently, the interaction of RGD motifs on the viral penton base with the cellular aVb3 and aVb5 integrins facilitates AdV entry via clathrin-mediated endocytosis. 48, 49 Although AdVs can infect a wide range of cell types, lymphocytes and DCs are not generally susceptible to AdV infection, in part because of the absence of CAR expression, 50, 51 which directly affects the therapeutic effect of engineered DC-based vaccines. Fiber-gene modification by insertion of RGD sequence in the viral fiber knob 0 s HI loop has been shown to enhance AdV infection of DCs through binding of RGD motif to DC integrins leading to enhanced DC-mediated antitumor immunity. 32, 52 To enhance DC infection, we constructed a recombinant RGD AdVneu with fiber-gene modification and transfected DCs with RGD AdVneu. We found that the transgene GFP expression was much higher in RGD AdVGFP-transfected DCs than in AdVGFP-transfected DCs. An approximate eightfold increase of transgene HER-2/neu expression in RGD AdVneu-transfected DCneu2 than in AdVneu-transduced DCneu1, indicating that transduction of DCs by RGD AdVneu is much more efficient than that of the original AdVneu without viral fiber modification.
Previous reports have shown that AdV transfection itself can stimulate DC maturation. 43, 53 In this study, our data also showed that the AdV-transduced DCneu upregulated the expression of immunologically important molecules (CD40, CD54, CD80 and CD86) and inflammatory cytokines (IL-6 and IL-12), compared with the untransduced DCs, indicating that AdV-transduced DC are more immunogenic form of DCs with high immune stimulatory properties and capability in stimulating both natural killer (NK) cells and CTLs. 43 For example, IL-6 is required for T cell activation and can convert Tr-mediated immune suppression. 54 IL-12 has pleiotropic effects on T cells and NK cells and functions for development of protective T-helper cell type 1 (Th1) cell responses. 55, 56 Therefore, upregulation of the above cytokines may play some role in DCneu-induced anti-HER-2/neu immunity.
The anti-HER2/neu humanized mAb Herceptin (trastuzumab) is being used to treat metastatic breast cancers and has been reported to inhibit tumor cell growth by downregulation of HER-2/neu expression. 57 In this study, we demonstrated that DCneu2 stimulated higher levels of HER-2/neu-specific IgG 2a and IgG 1 Ab than DCneu1 cells. We also showed that the immune sera containing anti-HER-2/neu Ab from mice immunized with DCneu2 also downregulated HER-2/neu expression and inhibited the growth of Tg1-1 tumor cells to a greater degree than the sera from DCneu1 immunized mice. In addition, DCneu2 vaccination stimulated stronger HER-2/neuspecific CD8 þ T-cell proliferation and CTL effector function than DCneu1 vaccine. More importantly, vaccination of DCneu2 cells stimulated significant anti-HER-2/neu immunity in vivo, which protected all mice Engineered DC vaccine in breast carcinoma S Sas et al from challenge of Tg1-1 tumor cells expressing the rat HER-2/neu Ag in wild-type FVB/NJ mice, whereas DCneu1 vaccine only protected 25% of mice from Tg1-1 tumor cell challenge, indicating that DCneu2 vaccine induced much stronger HER-2/neu-specific immunity than DCneu1 vaccine.
The FVBneuN Tg mice were derived from the parental FVB/NJ strain, express the wild-type rat HER-2/neu cDNA under the control of a mouse mammary tumor virus promoter. 58 Female mice spontaneously and stochastically develop mammary tumors in situ and small mammary tumors beginning at 2 and 4 months of age, respectively. 59 Because the HER-2/neu tumor Ag is endogenous to the host, this allows for development of tolerance to the self HER-2/neu Ag, as evidenced by the poor ability of these mice to develop HER-2/neu-specific antitumor immunity following vaccination as compared with the parental FVB/NJ mice. 60 Therefore, this mouse model of breast cancer that closely mimics immune tolerance described in some patients with cancer 61 becomes suitable for evaluating HER-2/neu-targeted vaccines. We have recently demonstrated that AdVneutransfected DC vaccine starting at 2-month age induced more significant delay of breast carcinoma development in Tg mice than that starting at 4 month age. 28 However, there were no case with complete prevention of breast carcinoma development in AdVneu-transfected DCimmunized Tg mice. The delay observed when immunizing mice with these DCs at a younger age may have been a result in the early generation of an effective immune response against HER-2/neu, but over time, the immune response declines in the presence of clinical tumors overexpressing HER-2/neu. 62 Therefore, in this study, we also selected to perform vaccination starting at 2-month age of FVBneuN mice. We demonstrated that DCneu2 vaccination delayed breast cancer growth in FVBneuN mice more significantly than DCneu1. More importantly, DCneu2, but not DCneu1 reduced breast carcinogenesis by 9% and significantly delayed tumor development in FVBneuN Tg mice, indicating that DCneu2 can stimulate more efficient anti-HER-2/neu CTL responses and partly overcome self-HER-2/neuspecific immune tolerance in Tg FVBneuN mice. To improve its efficacy, DCs engineered to express HER-2/ neu and cytokine genes have been proposed. For example, vaccination of DC engineered by two different AdV to express two transgenes such as HER-2/neu and TNF-a 23 or IL-12 22 has been shown to induce an augmented anti-HER-2/neu immunity than vaccination of DCs expressing HER-2/neu. It has recently been reported that DCs with staged IL-12 burst secretion significantly enhanced HER-2/neu-specific CD8 þ T-cell responses in clinical trials. 25 Therefore, DCs engineered to express both breast cancer Ag and cytokines may further enhance the antitumor immunity in DC-based vaccines of breast cancer for both prevention of breast cancer development and treatment of early breast cancer. Construction of fiber-modified AdV ( RGD AdVHER-2/TNF) expressing both HER-2/neu and inflammatory cytokine TNF-a and evaluation of the potential therapeutic effect of the AdV-transfected DC vaccine in treatment of early breast cancer in the Tg model are currently underway in our laboratory. Taken together, we demonstrated that the recombinant fiber-modified adenovirus RGD AdVneu has enhanced capacity by 8.3-fold to mediate DC transfection. The RGD AdVneu-transfected DCneu2 are more potent than AdVneu-transfected DCneu1 in induction of HER-2/neuspecific humoral and CTL responses. DCneu2 vaccination can protect wild-type FVB/NJ mice from Tg1-1 tumor cell challenge, significantly delay tumor growth and reduce breast carcinogenesis in Tg mice. Therefore, vaccination of fiber-modified adenovirus-transfected DCs to enhance expression of tumor Ags such as HER-2/neu is likely representative of a new direction in DC-based vaccine of breast cancer.
